Should You Continue to Retain Abbott Stock in Your Portfolio Now?

Abbott (ABT) has demonstrated strong operational performance, with its stock rallying 26.4% over the past year, significantly outpacing industry and S&P 500 gains. This growth is primarily fueled by robust demand in its Diagnostics division, including a $0.5 billion investment in expansion, and substantial momentum in its Diabetes Care segment, where FreeStyle Libre sales exceeded $1.7 billion in Q1 2025 following new OTC FDA approvals. Additionally, the Established Pharmaceuticals division achieved 8% organic growth in emerging markets, augmented by biosimilar deals. However, ABT faces headwinds from a challenging macroeconomic environment, which is increasing costs and potentially dampening demand, alongside unfavorable foreign exchange impacts that reduced Q1 sales by 2.8%.

Analysis

Abbott (ABT) exhibits a strong growth profile, underscored by its stock's 26.4% rally over the past year, significantly outpacing both its industry peer group (9%) and the S&P 500 (8.8%). This performance is anchored by robust operational execution in key segments. The Diabetes Care business is a primary driver, with sales of its continuous glucose monitoring (CGM) systems growing 21.6% to over $1.7 billion in the first quarter, propelled by the flagship FreeStyle Libre. Recent FDA approvals for over-the-counter versions, Lingo and Libre Rio, signal a major expansion of its addressable market. The Diagnostics division also shows strength, with Core Laboratory Diagnostics growing 6.5% ex-China and a $0.5 billion investment poised to expand its U.S. footprint. Furthermore, the Established Pharmaceuticals division delivered 8% organic growth in emerging markets, supported by a strategic push into biosimilars. However, these positive fundamentals are tempered by significant external pressures. A challenging macroeconomic environment is elevating raw material and freight expenses, posing a risk to margins. More tangibly, adverse foreign exchange movements reduced Q1 sales by 2.8%, a persistent headwind given the company's substantial international revenue base.

Key Decisions for Investors

• Investors should recognize the powerful growth trajectory in Abbott's Diabetes Care and Diagnostics segments, where flagship products like FreeStyle Libre and strategic investments are capturing significant market share and driving top-line results.
• It is critical to monitor the impact of macroeconomic pressures on operating margins and the persistent headwind from foreign currency fluctuations, which already eroded Q1 sales by 2.8% and could weigh on future earnings.
• Considering the stock's significant outperformance and the current balance between strong fundamental growth and external risks, a hold strategy appears warranted, with a focus on future earnings reports for any guidance changes related to margins or FX impacts.